1 Clinical Research Centre, Amager and Hvidovre Hospital, The Capital Region of Denmark2 Department of Infectious Diseases, Amager and Hvidovre Hospital, The Capital Region of Denmark
Hepatitis C virus (HCV) therapy will benefit from the preclinical evaluation of direct-acting antiviral (DAA) agents in infectious culture systems that test the effects on different virus genotypes. We developed HCV recombinants comprising the 5'UTR-NS5A (5-5A) from genotypes 1-6 and 2a(JFH1) NS5B-3'UTR, and tested the effects of NS3 protease and NS5A inhibitors on these recombinants.
Gastroenterology, 2014, Vol 146, Issue 3, p. 812-821
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't